Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 23, 2020

Primary Completion Date

November 2, 2020

Study Completion Date

November 10, 2023

Conditions
Oral CancerVEGFR2 InhibitorProgrammed Cell Death 1 InhibitorInductive Therapy
Interventions
DRUG

Camrelizumab

Inductive therapy with Camrelizumab of 200mg, iv, qd, on day 1, 15, 29.

DRUG

Apatinib

Inductive therapy with Apatinib of 250mg, po, qd, initiating on day 1, ending on the fifth day before surgery.

PROCEDURE

Radical surgery

Radical surgery will be performed on the 42th-45th after initiation of inductive therapy

RADIATION

Post-operative radiotherapy/chemoradiotherapy

Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathologic diagnosis.

Trial Locations (1)

200011

Shanghai Ninth People's Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT04393506 - Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter